We are a biopharmaceutical company primarily focused on the development and commercialization of proprietary biopharmaceutical products. We are developing prescription drugs for central nervous system (CNS) disorders and our current focus is the development of drugs with lower potential for abuse than currently available drugs. Our clinical-stage product currently under development is Abuse-Deterrent Amphetamine Immediate-Release, or ADAIR, a […]

We intend to focus on target companies in the technology industry, including those involved in software, communications, artificial intelligence, machine learning, data, analytics, 5G, IoT, cloud, edge, security, services and related areas. Our CEO is Arun Sarin, who previously was the CEO of Vodafone and Airtouch International. Our president is Ori Sasson, the founder and […]

We have not identified any potential business combination target and we have not, nor has anyone on our behalf, initiated any substantive discussions, directly or indirectly, with any potential business combination target. We intend to pursue a target in the disruptive commerce, digital media and services, and enterprise software sectors, with a primary focus on […]

We intend to focus our efforts on the financial services industry, specifically within alternative lending, asset management, business process outsourcing, housing and commercial real estate finance, insurance and tech-enabled business opportunities. Through our sponsor, we are affiliated with Waterfall Asset Management, an alternative asset manager, with approximately $8.3 billion in net assets under management (as of Aug. 1, […]

Our mission is to grow and empower local economies. Our journey began on January 12, 2013, when our founders launched a website displaying menus from local restaurants in Palo Alto, California. Within a few hours, the first DoorDash consumer ordered prawn pad thai and spring rolls from a nearby Thai eatery, and shortly afterwards, dinner was delivered […]

We intend to capitalize on the ability of our management team to identify, acquire and manage a business in the aviation, aerospace & defense, urban mobility and emerging technology industries that can benefit from our differentiated and proprietary deal flow, leading brand name and global network. We intend to focus our search on business combination targets […]

We are a clinical-stage biopharmaceutical company with one product candidate in a Phase 1/1b clinical trial, and we are focused on leveraging our proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases. Initially, we are applying our platform to create a […]

We expect to focus on a target in an industry where we believe our management team and founders’ expertise will provide us with a competitive advantage, including the financial services, healthcare, real estate services, technology and software industries. Howard W. Lutnick is our chairman and CEO. He joined Cantor in 1983. Mr. Lutnick has served […]

(Note: This is a blank-check company’s IPO (a unit offering) under the SAIL structure. SAIL is an acronym for Stakeholder Aligned Initial Listing securities. Each SAIL (SM) security has an offering price of  $10.00 and consists of one share of Class A common stock and one-fourth of one redeemable warrant. Each whole warrant entitles the holder thereof […]

The parent of our sponsor, CBRE, is the world’s largest commercial real estate services and investment firm, based on 2019 revenue, with leading global market positions in leasing, property sales, occupier outsourcing, property management, valuation and other business lines. We believe we will be able to leverage the advantages that CBRE holds by virtue of […]